In many clinical trials to evaluate treatment e cacy, i t i s b e l i e v ed that there may exist latent treatment e ectiveness lag times after which medical treatment procedure or chemical compound would be in full e ect. In this article, semiparametric regression models are proposed and studied to estimate the treatment e ect accounting for such latent lag times. The new models take advantage of the invariance property of the additive hazards model in marginalizing over random e ects, so parameters in the models are easy to be estimated and interpreted, while the exibility without specifying baseline hazard function is kept. Monte Carlo simulation studies demonstrate the appropriateness of the proposed semiparametric estimation procedure. Data collected in the actual randomized clinical trial, which e v aluates the e ectiveness of biodegradable carmustine polymers for treatment of recurrent brain tumors, are analyzed. Some key words: Change Point Clinical trials Cure models Mixture models Random e ects Semiparametric model Survival data.
Introduction
In comparative randomised clinical trials, e cacy of a new treatment, e.g., a new drug or medical procedure, is often assessed by comparing collected survival data. As expected, not all proposed treatments are always taking e ect as soon as their initiation. In fact, many treatments are observed to have slow onset of action after their initiation, such a s i n P erez et al. (1997) to assess the e cacy of an antidepressant treatment. For such phenomenon of slow onset of action, researchers often believe that there may exist a so-called treatment e ectiveness lag time before the treatment becomes fully e ective ( W u, Fisher & DeMets, 1980 Gail, 1985 Lakatos, 1986 Zucker & Lakatos, 1990 . A treatment e ectiveness lag time is the time for a biological subject to fully respond to medical procedures or compounds. It is usually not observable, although certain biomarkers can be used to arti cially de ne the termination of treatment e ectiveness lag time. If the treatment e ectiveness lag times are ignored, the assumptions of the widely-used proportional hazards model (Cox, 1972) with constant proportionality are often inappropriate and hence not able to correctly accommodate the observation of slow onset of action, unless some ad hoc time-dependent structure is included.
Although the existence of treatment e ectiveness lag time was recognized, in most of previous research i n d e v eloping appropriate statistical methodologies, researchers used the notion of a common xed treatment e ectiveness lag time for every individual or tried to nd ad hoc time-dependent lag functions for the proportional hazards model, for instance, in Self et al. (1988) and Zucker & Lakatos (1990) . But due to the heterogeneity among the biological subjects, such as unobservable di erent genotypes, the treatment e ectiveness lag times could apparently vary individual-by-individual. In addition, since prior knowledge about the lag is often rarely available, an accurate lag function is usually unknown and di cult to be determined.
To account for the latent treatment e ectiveness lag time and its heterogeneity among individuals, an unobservable random variable, U, s a y, i s i n troduced in this article to represent such lag time, which is treated as a random e ect. In addition, since some of the treatment e ectiveness lag times are too long to allow the full onset of action, a mixture cure model (Farewell, 1982 Gray & Tsiatis, 1989 Laska & Meisner, 1992 will be adapted for U. Furthermore, to identify the subject-dependent proportion of long-term treatment e ectiveness lag times, appropriate regression models will be incorporated into the mixture cure model.
One straightforward approach to estimate the treatment e ect accounting for the latent U is through the proportional hazards model. For a speci c example, given a treatment e ectiveness lag time U = u > 0, the relative hazards ratio can be assumed as 1 before u and after u. This is in fact the simplest version of the proportional hazards model with change point as random e ect (Nguyen, Rogers & Walker, 1984 Basu, Gosh & Joshi, 1988 . Although it carries simple form and straightforward interpretation conditioning on the random e ect, its marginalized version over the random e ect does not own clean multiplicative form any longer. This leads to some serious consequences, such a s \ n umerical and theoretical di culties" in inference procedures and \awkward interpretation" in parameters, as pointed out in Lin & Ying (1997) .
Instead of the multiplicative proportional hazards model, we will propose and study the change point hazards models with additive random e ects to determine the covariate e ect.
The remainder of this article is organized as follows. In x2, we will present the mixture model. The semiparametric inference procedures and its asymptotic properties are studied in x3. Numerical studies are demonstrated in x4. Some concluding remarks and discussion are in x5. Mathematical proofs are collected in Appendices.
The mixture model
Suppose that there are n independent participants in the study. For i = 1 2 : : : n , t h e failure time and censoring time for individual i are T i and C i , respectively and U i is the latent treatment e ectiveness lag time, i.e., after which the treatment is fully e ective. The actual observed data consist of the triplets of (X i i Z i ). Here X i = min(T i C i ) i s t h e survival time, and
is the censoring indicator, where I( ) is the indicator function taking the value of 1 if the condition is satis ed and 0 otherwise. Let superscript T denote the transpose of vector or matrix and Z i (t) = ( W T i (t) R T i (t)) T be the p-vector covariate. In particular, to estimate a treatment e ect such a s i n a t wo-arm randomised clinical trial, W i can be the treatment indicator being 1 if the participant is in the treatment group and 0 otherwise and R i (t) i s the concomitant risk factors or confounding variables, for which the treatment e ect needs to be adjusted, such as demographic variables or social-economic status. In addition, we assume that (T i C i ) are independent conditional on Z i .
Distribution of treatment e ectiveness lag times
In practice, it is noticeable that there exists possibility with which a portion of population may n e v er respond to the treatment. For example, when the treatment dosage does not meet the participant's minimal threshold for response, the treatment m a y n e v er be able to take full e ect. In this case, the treatment e ectiveness lag is considered as \long-term." Or, when the treatment e ectiveness lag time is relatively long enough to exceed certain pre-determined time point u 0 , e.g., 6 weeks in antidepressant therapy trials (P erez et al., 1997) , the treatment e ectiveness lag time is also considered as \long-term". Otherwise, the treatment e ectiveness lag time subject to early full treatment response is called \short-term."
Denote Y i the indicator of short-term treatment e ectiveness lag time for the ith participant, i.e. Y i = 1 if ith treatment e ectiveness lag time is short-term 0 if ith treatment e ectiveness lag time is long-term.
Furthermore, let F 0 (t ) = 1 ; F 0 (t ) be the conditional survival function for Y i = 1 , i = 1 2 : : : n . Then the treatment e ectiveness lag time U i 's survival function G i (t) = 1 ;G i (t), t 2 0 1) is assumed of the cure mixture model (Farewell, 1992) :
for i = 1 2 : : : n , where p i 2 0 1]. There are varieties of choices for F(t ), for example, distributions of Exponential, Weibull and Gamma.
From model (1), it seems in form that G i (t) is not a rigorously de ned distribution function in probability theory, whenever p i < 1. However, it implicitly carries the message that a treatment e ectiveness lag time can be long-term, or even in nite, which exactly describes the possible scenarios discussed above. If necessary, to make G i more statistically concrete, for example, an arti cial truncation time, u 0 , s a y, c a n b e c hosen. Then the form of G i (t) d o e s n o t c hange when 0 t u 0 but is 0 when t > u 0 (Laska & Meisner, 1992 Tamura, Faries & Feng, 2000 . Nevertheless, whether or not choosing a truncation time should not undermine the development of our proposed method in this article, as seen in the later development.
In model (1), p i is the probability o f t h e ith participant h a ving short-term treatment e ectiveness lag time. The larger the magnitude of p i , the easier the treatment t o b e f u l l y e ective within a reasonable time range. It can also be linked to the corresponding covariate Z i through appropriate regression models. For example, the logistic regression models (Farewell, 1992) can be used:
Other choices include probit, log-log and complementary log-log regression models (McCullagh & Nelder, 1989, p. 108 
where 0 = ( T 0 T 0 ) T is p-vector parameter and 0 (t) an unknown baseline hazard function. In model (3), conditional on the treatment e ectiveness lag time U i , the hazard function of Z i (t) i s 0 (t) + T 0 R i (t) before U i and 0 (t) + T 0 R i (t) + T 0 W i (t) a f t e r . Therefore, the parameter 0 characterizes the full e ect of W i (t) after the treatment e ectiveness lag time, which is often of the most interest, e.g., when W i (t) is the treatment indicator.
Model (3) is a change point model which generalizes the notion of xed treatment effectiveness lag time in Zucker & Lakatos (1990) by i n troducing heterogeneous treatment e ectiveness lag time U i 's. This re ects the truth that di erent individuals may h a ve different paces and hence di erent treatment e ectiveness lag times. Jointly, model (1) and (3) determine both the probability w i t h w h i c h the treatment e ect is fully e ective within a reasonable time range and the magnitude of full treatment e ect.
Model (3) is also an additive hazards model with random e ects. As argued in Breslow & D a y (1980 Breslow & D a y ( , p. 53-59 1987 and Lin & Ying (1997, p. 188-189) , an additive hazards model is able to provide sound interpretation in clinical studies. And, more importantly, it yields a much simpler marginal model after the random e ects are integrated. As shown in Appendix 1, the marginalized model (3) is:
where
and 0 = ( 0 0 ).
Assume that R i (t) and W i (t) are bounded. Furthermore, if there exists an i 0 2 f 1 2 : : : n g such that PrfU i 0 T i 0 g > 0, then it is easily seen that when p = 1 , Here, the additional assumption of PrfU i 0 T i 0 g > 0 i s a n i d e n ti ablity condition to secure the estimability of parameter 0 and the above properties. Otherwise, E I(U i T i ) T 0 W i (t)] 0 for any i and hence 0 is not estimable. This essentially requires that the treatment e ectiveness lag time is not always longer than the failure time for every individual in study.
In fact, H(t 0 0 ) corresponds to the lag function the researchers have been looking for. It is also of interest that H(t 0 0 ) o wns similar properties of cumulative distribution function (CDF). When W(t) 0, H(t) is exactly the distribution function of G, although its e ect on the hazard function is nulli ed by zero W(t). In x4, we will demonstrate what H(t 0 0 ) m a y a p p e a r t o b e b y studying some special H(t 0 0 )'s.
In general, the identi ability can be critical for models with arbitrary random e ects. This usually does not impose serious challenges upon model (3), as seen in the following theorem: which is straighforward to be established under the assumed conditions.
Inference Procedures and Asymptotic Properties
In this section, we present a semiparametric estimation procedure by fully utilizing the unaltered additive structure in model (3).
Let N i (t) = I(X i t i = 1 ) a n d Y i (t) = I(X i t), i = 1 2 : : : n . Consider the ltration F t de ned by F t = fN i (t) Y i (t) Z i (t) i = 1 2 : : : n g:
where P i (t ) = N i (t);
It is true that M i ( 0 0 ) are local square integrable martingales of F t . Therefore similar to the partial score equations for the proportional hazards model (Fleming & Harrington, 1991) , the following estimating equations can be used to estimate ( 0 0 ):
where Q(t 0 0 ) is a measurable weight function with respect to F t , w h i c h c o n verges uniformly to a deterministic function of q(t 0 0 ), and J i (t ) are smooth functions of same dimension of ( ), which are also predictable processes of t, i = 1 2 : : : n .
Although the baseline hazard function is unknown in (6), a reasonable estimator of 0 (t) of Breslow-type, nevertheless, iŝ
as in Lin and Ying (1994) . Thus we can use the following equations to estimate the parameters of interest:
Denote the left-hand side of equation (6) as ;( ). Some algebraic manipulation shows that ;( ) is equal to
To study the asymptotic properties of solutions by solving ;( ) = 0, we rst assume the following regularity conditions: 
where V ( 0 0 ) = V (t 0 0 0 ).
Proof. S e e Appendix 2.2.
In practice, to make inference about the estimates of parameters, it is natural to use the empirical estimates of its asymptotic variance-covariance matrix by its consistent estimator
Furthermore, replacing the parameters of ( ) w i t h ( ^ ) in (7) leads to a natural estimator of the cumulative baseline hazard function. As shown in Appendix 2.3, n 1=2 f^ 0 (t ^ ^ ); 0 (t)g converges weakly to a zero-mean Gaussian process with covariance function of (t 1 t 2 ), which is the limit of
) ;2 ds:
Although the proposed estimating equations can be viewed as parallel to the partial score equations for the proportional hazards model, they are still ad hoc. However, by t h e techniques in Lai & Ying (1992) and Lin & Ying (1994) , we can compute the semiparametric e ciency bound for the family of parametric submodels as ftjZ(t)g = 0 (t) + T R(t) + T W(t)H(t ) + (t) where , , and are parameters and ( ) is a xed function. As a result, the optimal estimating function for 0 is computed as:
However it is di cult to use ; opt in practice, because the estimating functions themselves involve the baseline hazard function. Although adaptive procedures using special techniques such as sample-splitting in Lin & Ying (1994) are available, the estimation of 0 always imposes an imminent c hallenge, especially when sample size is small.
To practically implement the optimal estimating functions, similar versions can be used instead for convenience. For example, one choice suggested in Lin & Ying (1994 is to use ; opt without including f 0 (t) + T R i (t) + T W i (t)H i (t )g ;1 , i . e . ,
Apparently, when the ignored term does not vary much from a constant, then ; should not lose much e ciency.
4 Numerical Studies
Examples of Lag Function H(t 0 0 )
As proposed in section 2.1, the distribution of G is a mixture cure distribution. In this section, we select some special G's to demonstrate their corresponding lag functions.
As seen in the de nition of G, F 0 (t) is in fact the conditional probability that the treatment e ectiveness lag time occurs after time t for short-term treatment e ectiveness lag times. One simple example is that let F 0 (t) be Exponential with survival function of: F 0 (t 0 ) = e ; 0 t I(t 0): Furthermore, let W(t) b e c o n s t a n t W 0 . T h e n H(t 0 0 ) = 0 p ( 0 ) 
as seen in Appendix 3.
In addition, if a truncation time is preferable, the truncated survival distribution of Exponential can be used (Gray & Tsiatis, 1989 Laska & Meisner, 1992 In addition, let W i (t) 1, 0 1 a n d 0 = 1 :01 1:5 2:0. Fig. 1 displays the lag functions when u 0 = 1. As shown in Figure 1 , since there is no truncation time for the treatment e ectiveness lag times, the nal lag functions are smooth. When p( 0 ) = 1, i.e, 100% shortterm treatment e ectiveness lag times, then marginally, the treatment will eventually reaches the full e ect in long run. But if there is any proportion of long-term treatment e ectiveness lag times, then the full e ect is not reachable, but instead, the treatment e ect is washed out in long run, although it may h a ve some e ect for early period of time. Since almost all the treatment e ectiveness lag times are assumed to happen before u 0 , it is not surprising to see similar patterns as in Fig. 1 before u 0 . In practice, since u 0 often serves as the termination of data collection, we should not be able to observe a n ything informative a f t e r u 0 . But as a demonstration, we still show the possible picture from simulation in Fig. 2 Nevertheless, as seen in both Figures 1 and 2 , when 0 is bigger, the treatment e ectiveness lag time becomes shorter, and then the mode of H tends to be reached earlier, which means the ultimate treatment e ect is reached faster.
More examples of lag functions obtained from Weibull and Gamma distributions can be found in Appendix 3. In addition, the derivatives of H with respect to di erent parameters are given as well.
Simulation Studies
Simulation studies have been conducted to study the performance of estimation procedure proposed in Section 3. Two c o variates are generated, R, w h i c h i s c o n tinuous, following the uniform distribution on 0,1], and W, w h i c h is 0 or 1 with equal probability of 1/2, mimicking a treatment indicator. The baseline hazards function is chosen to be a Weibull distribution.
Lag times are generated according to mixture distribution in (1) with F 0 to be exponential and p( 0 ) to be constant. Then Failure times are generated according to model (3), with ( 0 0 ) = ( 0 0), (0,1) and (1,0). Independent censoring times are generated from exponential distribution with di erent means to yield two censoring percentages of approximately 25% and 50%. Sample sizes are of 100 and 200. Estimating functions in (11) will be used for parameter estimation.
Simulation results are listed in Table 1 . For each e n try in the table, one thousand replicates are simulated to compute the bias and empirical coverage probability. Here, bias is de ned as the di erence between the sample mean of the estimates over the 1,000 simulated data sets and its respective t r u e v alue and 95% emipirical coverage probability i s t h e percentage of Wald-type 95% con dence intervals that include the true parameters. It is evident that the estimators are virtually unbiased and the nominal con dence intervals for the parameters have reasonable coverage probabilities. 
Real Data Examples
The data to be analyzed are collected from a randomised placebo-controlled trial of the effectiveness of biodegradable carmustine polymers for treatment of recurrent brain malignant gliomas (Brem et al. 1995) . After the recurrent brain tumor was removed, a medicated or placebo polymer was placed to ll in the cavity. T o reach a higher local drug concentration, the medicated polymers were supposed to gradually release carmustine over a 2 to 3 week period following the placement, because it would be more e ective than systematic application (Tamargo et al., 1993 Brem et al., 1995 . In 27 medical centers of this trial, 222 patients were randomized to either the carmustine polymer treatment group (110 patients) or the placebo polymer group (112 patients). Their survival times measured in weeks, treatment assignment and prognostic factors can be found in Piantadosi (1997, p. 496-509) . Some exploratory analysis results can be found in Brem et al. (1995) and Chen & Wang (2000) .
In addition to the treatment indicator (W ), another prognostic covariate of age (R) is also considered for analysis. Results from the proportional hazards model (tjZ) = 0 (t) exp( Z), the additive hazards model (tjZ) = 0 (t) + Z and the proposed model (3) that assumes the exponential F 0 and logistic model for response proportions, are listed in Table 2 . As shown in the table, after adjusting for age, although the treatment e ect does not appear signi cant in either the proportional hazards model or the additive hazards model, it is signi cant if the treatment e ectiveness lag time is taken into account. That is, given the presence of the lag time, the treatment will signi cantly decrease the hazard of placebo group by 0.014, adjusting for age. The estimated average treatment e ectiveness lag time is about 2.502 weeks for those who have short-term lag times. Its con dence interval does not contain 0, which implies the signi cant presence of such lag times. In fact, as shown in Figure 1 of Chen & Wang (2000) , the two groups are almost indistinguishable till the 7th or 8th week, if the e ect of age is ignored, which also graphically suggests the potential existence of such lag time. Furthermore, because of the non-signi cant 's, the proportions of the short-term responders seem not varying according to treatment assignment or participant's age. 
Remarks
A more general mixture model for the treatment e ectiveness lag time is G(t) = p F 1 (t) + ( 1 ; p) F 2 (t) (13) where F 1 (t) is the survival function for p proportion of treatment e ectiveness lag times and F 2 (t) is the survival function for the remaining proportion, 1 ; p. T o see this, let F 2 (t) 1, then model (13) becomes the cure mixture model. Furthermore, if the hazard function of F 1 is monotonically increasing, we should expect the hazard function of treatment e ectiveness lag time to be initially increasing but decreasing later, as the p proportion of short-term treatment e ectiveness lag times dropping out of the risk set with relatively more long-term treatment e ectiveness lag times left.
In the potential presence of treatment e ectiveness lag time, the so-called \intention-to-treat" principle (Sheiner & Rubin, 1995) may be arguable to be used to estimate the full treatment e ect. For example, if W(t) is a binary treatment indicator taking the value of 0 or 1 as assumed in model (3), then given the treatment e ectiveness lag time U, t h e treatment will not be fully e ective before U, i.e., it is still a true \control" before U.
Therefore marginally, he or she should be equivalently counted as a member of treatment with probability o f H(t 0 0 ) exactly, although the participant i s p h ysically assigned to the treatment group. As shown in Fig. 1 , when 0 increases as in the Exponential distribution, i.e., the treatment e ectiveness lag time tends to be shorter, the treatment reaches its full e ect quicker.
In Model (3), the most critical part is the random e ects are additive to possibly gain bene t in designing simple inference procedures. It is less critical whether or not the xed e ect of R i (t) t o b e a d d i t i v e o r m ultiplicative. Thus another class of change point hazards models with additive random e ects is:
In contrast to the general additive-multiplicative hazards model in Lin & Ying (1995) , it is not to di cult to nd that model (14) Although the model proposed in this article has certain prominent a d v antages, there are some critical issues in actually implementing this model. The rst issue is inherited from the additive hazards model. That is, the parameter space is restricted by the magnitude of the baseline hazard function in order to obtain reasonable parameter estimates. One solution is to replace Zwith exp( Z), but then the interpretation of becomes cumbersome. The second issue is inherited from the cure mixture model, which is the potential identi ability problem with the parameters in the regression model of response proportions and the parameters in F 0 . A s p o i n ted out by F arewell (1998, p. 1051-2) , the estimates of these parameters here also tend to have high correlation because of possible over-parametrisation of the lag times. This issue would be less critical if there is strong pathological evidence to support the notion of existence of two heterogeneous population. Otherwise, only modelling F 0 but ignoring p's is good enough to detect the potential existence of the lag time, estimate its average and derive a good lag function in practice. The second term on the right-hand side in the above equation is an average of martingale integrals, therefore it converges in probability to zero. With the conditions in Theorem 3, it is true that the rst term converges to A. Therefore, ;n; 0 (t 0 0 0 ) P ! D. In fact, following similar arguments in Lin & Ying (1995) , it is also true that (^ T ^ T ) T ! ( Table 1 : Summary of simulation studies. Each e n try is the estimated bias, with the associated 95% empirical coverage probability i n b r a c kets. 
